RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation
Open Access
- 14 January 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 843
Abstract
Multiple myeloma (MM) is a challenging hematologic malignancy characterized by clonal plasma cell proliferation, often leading to significant morbidity and mortality worldwide. Despite advances in chemotherapy and CAR-T therapies, MM remains incurable due to tumor heterogeneity, immune evasion, and microenvironment remodeling—exacerbated by toxicities like cytokine release syndrome and myelosuppression. This urgent unmet need demands innovative strategies. In this review, we assess cutting-edge RNA-based therapeutics for MM modulation, drawing on preclinical and clinical evidence on modalities including mRNA vaccines, small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNA (miRNA) mimics/inhibitors. We further explore RNA-engineered cell therapies, such as transient CAR-T platforms and lipid nanoparticle-delivered systems targeting the bone marrow niche. By integrating these insights, we underscore RNA technologies’ transformative potential to achieve durable remissions, overcome resistance, and reduce costs—paving the way for personalized, safer treatments in refractory MM.Keywords
Funding Information
- This work was supported by the grant of the state program of the «Sirius» Federal Territory «Scientific and technological development of the «Sirius» Federal Territory» (Agreement No. 18-03 on 10 September 2024))
This publication has 400 references indexed in Scilit:
- Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA ExcisionAdvanced Healthcare Materials, 2025
- Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2024
- Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer ImmunotherapyAdvanced Materials, 2024
- Spleen SORT LNP Generated in situ CAR T Cells Extend Survival in a Mouse Model of Lymphoreplete B Cell LymphomaAngewandte Chemie International Edition, 2023
- Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosisCancer Medicine, 2023
- Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38‐Targeted Lipid NanoparticlesAdvanced Science, 2023
- NAT10‐mediated mRNA N4‐acetylcytidine modification promotes bladder cancer progressionClinical and Translational Medicine, 2022
- Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple MyelomaJAMA Network Open, 2021
- Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomibCell Biology International, 2020
- The mechanism study of miR‐125b in occurrence and progression of multiple myelomaCancer Medicine, 2017